20/20 Licenses Lung Cancer Blood Test to Ortho-Clinical Diagnostics
The company has entered into an agreement with Ortho-Clinical Diagnostics to license certain 20/20 intellectual property relating to a blood test for the early detection of lung cancer.
LabCorp Licenses Technology for Early Detection of Lung Cancer from Duke University
LabCorp enters into an exclusive license agreement to commercialize Duke's new blood-based assay for early detection of lung cancer.
Common Molecule Notifies Immune System of Prostate Cancer
In experiments with mice, researchers have found that the body's immune system can use a surprisingly common molecule to recognize prostate tumors.
Oncology Metrics and Cureline Announce Joint Marketing Agreement
Both companies have reached an agreement to collaborate on oncology biospecimen procurement and management.
Luminex Receives U.S. Food and Drug Administration Clearance for xTAG™ Respiratory Viral Panel
The Company has designed the test to simultaneously detect the most prevalent respiratory viruses.
Breast Cancer Cells Have to Learn to Walk Before they can Run
Early stage breast cancer that has not yet invaded the surrounding tissues may already contain highly motile cells, which brings the tumor one step closer to metastasis.
Pfizer to Acquire CovX to Extend Biotherapeutics Investment
Acquisition will provide biotherapeutics technology platform and complementary product candidates in oncology and diabetes.
Nicholas Piramal Enters into a Joint Venture with ARKRAY Inc Japan
The 49:51 joint venture aims at marketing diagnostic products, mainly self-monitoring blood glucose system in the Indian market.
BD Acquires Right to Negotiate Business Relationship for Accelr8’s BACcel® Technology
Becton Dickinson has purchased an exclusive right to negotiate for a business relationship to develop Accelr8’s BACcel® rapid diagnostic platform.
Cancer Cell Line Developed that is Resistant to new Cancer Therapy
Researchers found the HDAC inhibitor-resistant cell line resistant to many therapies but highly sensitive to heat shock protein 90 inhibitors, another emerging cancer treatment.